Clinical Trial: Comparison of Medical Therapies in Marfan Syndrome.
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial
Brief Summary: The investigators are looking at the different impacts of atenolol, verapamil and perindopril on large artery and lv function in marfan syndrome. It is a double-blind, randomised cross-over trial.
Detailed Summary:
The investigators recruited 21 patients with confirmed diagnosis of Marfan syndrome from two centres. The investigators performed radial artery applanation tonometry and pulse wave analysis to derive central aortic pressure and haemodynamic indexes pre-and post administering Atenolol 75mg, Perindopril 4mg and Verapamil 240mgs each for four weeks with a two week wash-out between medications. All patients underwent detailed functional and anatomical echocardiographic assessments at each visit.
Inclusion criteria were ages 16-60 years with no treatment or β-blocker or other monotherapy only for Marfan syndrome. Patients with previous aortic dissection or aortic surgery, severe valvular regurgitation, aortic diameter at the sinotubular junction ≥ 5.0cm, contraindications to specific drug treatment, e.g. asthma and β-blocker, or those who were pregnant or at risk of pregnancy were excluded.
Sponsor: Cardiff University
Current Primary Outcome: CENTRAL ARTERIAL PRESSURE [ Time Frame: 18 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- LARGE ARTERIAL STIFFNESS INDICES [ Time Frame: 18 WEEKS ]MEASURED BY ECHO AND BY PULSE WAVE VELOCITY/ANALYSIS BY APPLANATION TONOMETRY
- LV Function [ Time Frame: 18 WEEKS ]GLOBAL AND REGIONAL MARKERS BY ECHO
Original Secondary Outcome: Same as current
Information By: Cardiff University
Dates:
Date Received: February 11, 2011
Date Started: July 2006
Date Completion:
Last Updated: February 11, 2011
Last Verified: January 2006